Evidence map›Paper›PMID 35410606›Full record

ArticleCurrent neuropharmacology2023

Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.

Marco Di Nicola, Bernardo Dell'Osso, Ilaria Peduto, Riccardo Cipelli, Anna Cristina Pugliese, Maria Salvina Signorelli, Antonio Ventriglio, Giovanni Martinotti

Open access · bronzeAbstract read
In one paragraph

Article in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Marco Di NicolaDepartment of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Bernardo Dell'OssoDepartment of Biomedical and Clinical Sciences Luigi Sacco, Aldo Ravelli Center for Neurotechnology and Brain Therapeutic, University of Milan, Milan, Italy.
Ilaria PedutoIQVIA Solutions Srl, Milano, Italy.
Riccardo CipelliIQVIA Solutions Srl, Milano, Italy.
Anna Cristina PuglieseMedical Department Lundbeck, Italia.
Maria Salvina SignorelliDepartment of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, via Santa Sofia 78, 95123 Catania, Italy.
Antonio VentriglioDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Giovanni MartinottiDepartment of Neuroscience, Imaging and Clinical Sciences, University "G. D'Annunzio" of Chieti - Pescara, Chieti, Italy.
Agostino Gemelli University Polyclinic · ITLundbeck (Germany) · DEUniversity of Catania · ITUniversity of Chieti-Pescara · ITUniversity of Foggia · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor depressive disorders represent a significant burden to society, and it is recommended that antidepressant therapy should last at least 6 months. In Italy, antidepressant use in clinical practice was reported to increase by 1.7% in 2020 compared to 2019, but only 40% of new prescriptions are characterized by a treatment duration longer than 3 months.

objectiveThe study aims to describe adherence and persistence to therapy in a subset of antidepressants (citalopram, duloxetine, escitalopram, paroxetine, sertraline, venlafaxine) vs. vortioxetine in Italy during a 2-year period from 2017 to 2019.

methodsA retrospective analysis of the longitudinal patient database reporting data from general practitioners on drug prescriptions in Italy was carried out in a cohort of 8,235 adult patients who were prescribed antidepressants.

resultsOverall, 32.4% of the patients adhered to treatment for ≥6 months over a 1-year period. Vortioxetine had a lower risk of low adherence compared to duloxetine, paroxetine, and venlafaxine and a higher risk compared to citalopram, escitalopram, and sertraline. 68.7% of patients discontinued treatment during follow-up. The greatest percentage of patients continuing therapy was seen with duloxetine, while citalopram was associated with the highest proportion of patients discontinuing therapy. No significant differences in discontinuation were observed when comparing vortioxetine to the other antidepressants.

conclusionAdherence results were considerably less than the 6-month recommendation in this real- world analysis of antidepressant therapies. Also, persistence to therapy was low, with most patients discontinuing treatment. Thus, there is a need for interventions to help patients adhere to their planned therapy.

Indexed as

Major Depressive DisorderAdultAntidepressive AgentsCitalopramDuloxetine HydrochlorideEscitalopramHumansItalyParoxetineRetrospective StudiesSertralineVenlafaxine HydrochlorideVortioxetineAntidepressive AgentsCitalopramDuloxetine HydrochlorideEscitalopramParoxetineSertralineVenlafaxine HydrochlorideVortioxetineAdherenceantidepressantsmajor depressive disorderspersistencereal-world evidenceretrospective study

Identifiers

PMID35410606
PMCPMC10207922
OpenAlexW4223564240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.